You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDipyridamole
Accession NumberDB00975  (APRD00360)
TypeSmall Molecule
GroupsApproved
DescriptionA phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Structure
Thumb
Synonyms
Cardoxin
Cleridium 150
Curantyl
Dipiridamol
Dipyridamine
Dipyridamolum
Dipyudamine
Dypyridamol
Persantin
External Identifiers
  • USAF GE-12
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dipyridamoletablet25 mg/1oralCarilion Materials Management2012-02-15Not applicableUs
Dipyridamoletablet25 mg/1oralRoxane Laboratories, Inc.2012-02-15Not applicableUs
Dipyridamoletablet50 mg/1oralRoxane Laboratories, Inc.2012-02-15Not applicableUs
Dipyridamoletablet75 mg/1oralRoxane Laboratories, Inc.2012-02-15Not applicableUs
Dipyridamole 25 Tab 25mgtablet25 mgoralPro Doc Limitee1983-12-312002-08-02Canada
Dipyridamole 50 Tab 50mgtablet50 mgoralPro Doc Limitee1983-12-312002-08-02Canada
Dipyridamole 75 Tabtablet75 mgoralPro Doc Limitee1984-12-312002-08-02Canada
Dipyridamole for Injectionsolution5 mgintravenousNovopharm Limited2002-04-30Not applicableCanada
Dipyridamole Injection, USPliquid5 mgintravenousFresenius Kabi Canada Ltd2002-04-23Not applicableCanada
Dipyridamole-25tablet25 mgoralPro Doc Limitee1998-08-282010-07-13Canada
Dipyridamole-50tablet50 mgoralPro Doc Limitee1998-08-282010-07-13Canada
Dipyridamole-75tablet75 mgoralPro Doc Limitee1998-08-282010-07-13Canada
Novo-dipiradol Sct 100mgtablet100 mgoralNovopharm Limited1991-12-312005-08-10Canada
Novo-dipiradol Tab 25mgtablet25 mgoralNovopharm Limited1989-12-312005-08-10Canada
Novo-dipiradol Tab 50mgtablet50 mgoralNovopharm Limited1989-12-312005-08-10Canada
Novo-dipiradol Tab 75mgtablet75 mgoralNovopharm Limited1989-12-312005-08-10Canada
Persantinetablet, coated50 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
Persantinetablet, coated75 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
Persantinesolution5 mgintravenousBoehringer Ingelheim (Canada) Ltd Ltee1986-12-31Not applicableCanada
Persantinetablet, coated25 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.1999-06-01Not applicableUs
Persantine Tab 100mgtablet100 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1985-12-312002-07-25Canada
Persantine Tab 25mgtablet25 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1962-12-312005-02-14Canada
Persantine Tab 50mgtablet50 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1968-12-312011-03-03Canada
Persantine Tab 75mgtablet75 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1981-12-312010-06-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-dipyridamole-FC Tab 25mgtablet25 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-FC Tab 50mgtablet50 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-FC Tab 75mgtablet75 mgoralApotex Inc1990-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 25mgtablet25 mgoralApotex Inc1982-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 50mgtablet50 mgoralApotex Inc1982-12-31Not applicableCanada
Apo-dipyridamole-SC Tab 75mgtablet75 mgoralApotex Inc1984-12-31Not applicableCanada
Dipyridamoletablet, film coated50 mg/1oralCardinal Health2008-10-30Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralBarr Laboratories Inc.1982-01-01Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralAv Kare, Inc.2007-07-08Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
Dipyridamoletablet25 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralMajor Pharmaceuticals2008-10-30Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralRising Pharmaceuticals, Inc.2007-02-13Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralLannett Company, Inc.2008-04-23Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralAv Pak2011-08-052016-01-15Us
Dipyridamoletablet, film coated50 mg/1oralCardinal Health2011-08-05Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralBarr Laboratories Inc.1982-01-01Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralAv Kare, Inc.2007-07-08Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
Dipyridamoletablet50 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralCadila Healthcare Limited2008-05-22Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralMajor Pharmaceuticals2008-10-30Not applicableUs
Dipyridamoleinjection, solution5 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-09-01Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralLannett Company, Inc.2008-04-23Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-23Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralRising Pharmaceuticals, Inc.2007-08-05Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralAvera Mc Kennan Hospital2015-11-17Not applicableUs
Dipyridamoletablet75 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2007-07-18Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralAv Pak2007-08-052016-01-15Us
Dipyridamoletablet, film coated75 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-05-22Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralCadila Healthcare Limited2008-05-22Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralMajor Pharmaceuticals2008-10-30Not applicableUs
Dipyridamoletablet, film coated75 mg/1oralCardinal Health2008-10-30Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralBarr Laboratories Inc.1980-10-01Not applicableUs
Dipyridamoleinjection5 mg/mLintravenousWest Ward Pharmaceutical Corp.1996-10-18Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralRising Pharmaceuticals, Inc.2007-02-13Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralLannett Company, Inc.2008-04-23Not applicableUs
Dipyridamoletablet, film coated50 mg/1oralAv Pak2011-08-052016-01-15Us
Dipyridamoletablet, film coated75 mg/1oralCadila Healthcare Limited2008-05-22Not applicableUs
Dipyridamoletablet, film coated25 mg/1oralAv Kare, Inc.2007-07-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dipyridamolesolution5 mg/mLintravenousAnazao Health Corporation2012-05-23Not applicableUs
International Brands
NameCompany
Agileaselsei
CardoxinRafa
Cleridium 150Millot
CurantylArzneimittelwerk
PersantinNot Available
Brand mixtures
NameLabellerIngredients
AggrenoxBoehringer Ingelheim Pharmaceuticals, Inc.
Asasantine CapBoehringer Ingelheim (Canada) Ltd Ltee
Aspirin and DipyridamoleRoxane Laboratories, Inc.
SaltsNot Available
Categories
UNII64ALC7F90C
CAS number58-32-2
WeightAverage: 504.6256
Monoisotopic: 504.317251808
Chemical FormulaC24H40N8O4
InChI KeyInChIKey=IZEKFCXSFNUWAM-UHFFFAOYSA-N
InChI
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
IUPAC Name
2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol
SMILES
OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassTertiary amines
Direct ParentDialkylarylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Aminopyrimidine
  • Imidolactam
  • Pyrimidine
  • Piperidine
  • Heteroaromatic compound
  • Azacycle
  • Organoheterocyclic compound
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
PharmacodynamicsDipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.
Mechanism of actionDipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.
Related Articles
Absorption70%
Volume of distribution
  • 1 to 2.5 L/kg
Protein binding99%
Metabolism

hepatic

Route of eliminationDipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.
Half life40 minutes
Clearance
  • 2.3-3.5 mL/min/kg
ToxicityHypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD50 in rats is greater than 6,000 mg/kg while in the dogs, the oral LD50 is approximately 400 mg/kg. LD50=8.4g/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Dipyridamole (Antiplatelet) Action PathwayDrug actionSMP00264
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier-0.6246
Caco-2 permeable-0.7261
P-glycoprotein substrateSubstrate0.7696
P-glycoprotein inhibitor INon-inhibitor0.5321
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.615
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateNon-substrate0.6825
CYP450 3A4 substrateNon-substrate0.6849
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8045
CYP450 2D6 inhibitorInhibitor0.7201
CYP450 2C19 inhibitorNon-inhibitor0.957
CYP450 3A4 inhibitorInhibitor0.6789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7806
Ames testNon AMES toxic0.7009
CarcinogenicityNon-carcinogens0.8884
BiodegradationNot ready biodegradable0.988
Rat acute toxicity2.1167 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5271
hERG inhibition (predictor II)Non-inhibitor0.633
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis totowa llc
  • Barr laboratories inc
  • Glenmark generics inc usa
  • Impax laboratories inc
  • Lannett holdings inc
  • Murty pharmaceuticals inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Boehringer Ingelheim Pharmaceuticals, Inc
Packagers
Dosage forms
FormRouteStrength
Capsule (extended release); capsule (immediate release)oral
Tabletoral25 mg
Tabletoral50 mg
Tabletoral75 mg
Capsuleoral
Injectionintravenous5 mg/mL
Injection, solutionintravenous5 mg/mL
Solutionintravenous5 mg/mL
Tabletoral25 mg/1
Tabletoral50 mg/1
Tabletoral75 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral75 mg/1
Liquidintravenous5 mg
Tabletoral100 mg
Solutionintravenous5 mg
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Tablet, coatedoral75 mg/1
Prices
Unit descriptionCostUnit
Dipyridamole powder5.34USD g
Aggrenox capsule sa3.25USD capsule
Aggrenox 25-200 mg 12 Hour Capsule3.0USD capsule
Dipyridamole 5 mg/ml ampul1.5USD ml
Persantine 75 mg tablet1.46USD tablet
Dipyridamole 5 mg/ml vial1.32USD ml
Dipyridamole 75 mg tablet1.28USD tablet
Persantine 50 mg tablet1.09USD tablet
Dipyridamole 50 mg tablet0.96USD tablet
Persantine 25 mg tablet0.89USD tablet
Dipyridamole 25 mg tablet0.58USD tablet
Apo-Dipyridamole (Fc) 75 mg Tablet0.46USD tablet
Apo-Dipyridamole (Fc) 50 mg Tablet0.31USD tablet
Apo-Dipyridamole (Fc) 25 mg Tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6015577 No1997-01-182017-01-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point163 °CPhysProp
water solubilitySlightlyNot Available
logP1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.922 mg/mLALOGPS
logP1.52ALOGPS
logP1.81ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)14.97ChemAxon
pKa (Strongest Basic)6.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area145.44 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity142.78 m3·mol-1ChemAxon
Polarizability56.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Minutza Leibovici, Itamar Kanari, Michael Fox, “Dipyridamole extended-release formulations and process for preparing same.” U.S. Patent US20070184110, issued August 09, 2007.

US20070184110
General References
  1. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. [PubMed:8981292 ]
External Links
ATC CodesB01AC07
AHFS Codes
  • 24:12.92
PDB EntriesNot Available
FDA labelDownload (48.7 KB)
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Dipyridamole.
AbciximabDipyridamole may increase the anticoagulant activities of Abciximab.
AcebutololDipyridamole may increase the bradycardic activities of Acebutolol.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dipyridamole.
AcenocoumarolDipyridamole may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Dipyridamole.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Dipyridamole.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dipyridamole.
AdenosineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Adenosine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dipyridamole.
AlbendazoleThe serum concentration of Dipyridamole can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.
AldosteroneThe serum concentration of Dipyridamole can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dipyridamole.
AlectinibThe serum concentration of Dipyridamole can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Dipyridamole can be increased when it is combined with Alfentanil.
AliskirenThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Dipyridamole.
AlprenololDipyridamole may increase the bradycardic activities of Alprenolol.
AlprostadilAlprostadil may increase the anticoagulant activities of Dipyridamole.
AlprostadilDipyridamole may increase the antiplatelet activities of Alprostadil.
AlteplaseDipyridamole may increase the anticoagulant activities of Alteplase.
ALX-0081Dipyridamole may increase the anticoagulant activities of ALX-0081.
AmantadineThe serum concentration of Dipyridamole can be increased when it is combined with Amantadine.
AmbenoniumThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Dipyridamole.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Dipyridamole.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dipyridamole.
Aminohippuric acidThe serum concentration of Dipyridamole can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dipyridamole.
AmiodaroneThe serum concentration of Dipyridamole can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Dipyridamole.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dipyridamole.
AmobarbitalAmobarbital may increase the hypotensive activities of Dipyridamole.
AmprenavirThe serum concentration of Dipyridamole can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Dipyridamole can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Amyl Nitrite.
AnagrelideAnagrelide may increase the anticoagulant activities of Dipyridamole.
AncrodDipyridamole may increase the anticoagulant activities of Ancrod.
AnistreplaseDipyridamole may increase the anticoagulant activities of Anistreplase.
Antithrombin III humanDipyridamole may increase the anticoagulant activities of Antithrombin III human.
ApixabanDipyridamole may increase the anticoagulant activities of Apixaban.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Dipyridamole.
AprotininThe therapeutic efficacy of Dipyridamole can be decreased when used in combination with Aprotinin.
ArdeparinDipyridamole may increase the anticoagulant activities of Ardeparin.
ArgatrobanDipyridamole may increase the anticoagulant activities of Argatroban.
AripiprazoleAripiprazole may increase the hypotensive activities of Dipyridamole.
ArotinololDipyridamole may increase the bradycardic activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Dipyridamole.
AstaxanthinDipyridamole may increase the anticoagulant activities of Astaxanthin.
AstemizoleThe serum concentration of Dipyridamole can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Dipyridamole.
AtenololDipyridamole may increase the bradycardic activities of Atenolol.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Dipyridamole.
AtorvastatinThe serum concentration of Dipyridamole can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Dipyridamole.
AzelastineAzelastine may increase the anticoagulant activities of Dipyridamole.
AzelastineDipyridamole may increase the antiplatelet activities of Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Dipyridamole can be increased when it is combined with Azithromycin.
BarbitalBarbital may increase the hypotensive activities of Dipyridamole.
BatroxobinDipyridamole may increase the anticoagulant activities of Batroxobin.
BecaplerminDipyridamole may increase the anticoagulant activities of Becaplermin.
BefunololDipyridamole may increase the bradycardic activities of Befunolol.
BemiparinDipyridamole may increase the anticoagulant activities of Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dipyridamole.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dipyridamole.
BenzocaineThe serum concentration of Dipyridamole can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Dipyridamole can be increased when it is combined with Bepridil.
BeraprostDipyridamole may increase the anticoagulant activities of Beraprost.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Dipyridamole.
BetaxololDipyridamole may increase the bradycardic activities of Betaxolol.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dipyridamole.
BevantololDipyridamole may increase the bradycardic activities of Bevantolol.
BiperidenThe serum concentration of Dipyridamole can be increased when it is combined with Biperiden.
BisoprololDipyridamole may increase the bradycardic activities of Bisoprolol.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dipyridamole.
BivalirudinDipyridamole may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Dipyridamole.
BopindololDipyridamole may increase the bradycardic activities of Bopindolol.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Dipyridamole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Dipyridamole.
BretyliumThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dipyridamole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Dipyridamole.
BufuralolDipyridamole may increase the bradycardic activities of Bufuralol.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dipyridamole.
BupranololDipyridamole may increase the bradycardic activities of Bupranolol.
BuprenorphineThe serum concentration of Dipyridamole can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Dipyridamole can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Dipyridamole.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Dipyridamole.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Dipyridamole.
CanagliflozinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Dipyridamole.
CangrelorDipyridamole may increase the anticoagulant activities of Cangrelor.
CaptoprilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Captopril.
CarbamazepineThe serum concentration of Dipyridamole can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Dipyridamole.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Dipyridamole.
CarteololDipyridamole may increase the bradycardic activities of Carteolol.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Dipyridamole.
CarvedilolDipyridamole may increase the bradycardic activities of Carvedilol.
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dipyridamole.
CaspofunginThe serum concentration of Dipyridamole can be increased when it is combined with Caspofungin.
CeliprololDipyridamole may increase the bradycardic activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Dipyridamole.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Dipyridamole.
CertoparinDipyridamole may increase the anticoagulant activities of Certoparin.
ChloroquineThe serum concentration of Dipyridamole can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dipyridamole.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Dipyridamole.
ChlorpropamideThe serum concentration of Dipyridamole can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Dipyridamole can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dipyridamole.
CholesterolThe serum concentration of Dipyridamole can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Dipyridamole can be decreased when it is combined with Cholic Acid.
CilazaprilThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Cilazapril.
CilostazolDipyridamole may increase the anticoagulant activities of Cilostazol.
CimetidineThe serum concentration of Dipyridamole can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Dipyridamole.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Dipyridamole.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Dipyridamole.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Dipyridamole.
Citric AcidDipyridamole may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Dipyridamole.
ClevidipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Dipyridamole.
ClofazimineThe serum concentration of Dipyridamole can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Dipyridamole.
ClomipramineThe serum concentration of Dipyridamole can be increased when it is combined with Clomipramine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dipyridamole.
ClopidogrelClopidogrel may increase the anticoagulant activities of Dipyridamole.
ClotrimazoleThe serum concentration of Dipyridamole can be decreased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Dipyridamole.
CobicistatThe serum concentration of Dipyridamole can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Dipyridamole.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Dipyridamole.
ColforsinThe serum concentration of Dipyridamole can be increased when it is combined with Colforsin.
CollagenaseThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Collagenase.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Dipyridamole.
CoumaphosThe therapeutic efficacy of Coumaphos can be decreased when used in combination with Dipyridamole.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Dipyridamole.
CyclophosphamideThe serum concentration of Dipyridamole can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Dipyridamole can be decreased when it is combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Dipyridamole.
Dabigatran etexilateDipyridamole may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Dipyridamole.
DaclatasvirThe serum concentration of Dipyridamole can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Dipyridamole.
DalteparinDipyridamole may increase the anticoagulant activities of Dalteparin.
DanaparoidDipyridamole may increase the anticoagulant activities of Danaparoid.
DapagliflozinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.
DasatinibDasatinib may increase the anticoagulant activities of Dipyridamole.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Dipyridamole.
DaunorubicinThe serum concentration of Dipyridamole can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Dipyridamole.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Dipyridamole.
DecamethoniumThe therapeutic efficacy of Decamethonium can be decreased when used in combination with Dipyridamole.
DefibrotideDipyridamole may increase the anticoagulant activities of Defibrotide.
DemecariumThe therapeutic efficacy of Demecarium can be decreased when used in combination with Dipyridamole.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Deoxycholic Acid.
DesipramineThe serum concentration of Dipyridamole can be increased when it is combined with Desipramine.
DesirudinDipyridamole may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Dipyridamole can be increased when it is combined with Desloratadine.
DesmoteplaseDipyridamole may increase the anticoagulant activities of Desmoteplase.
DexamethasoneThe serum concentration of Dipyridamole can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Dipyridamole.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dipyridamole.
DextranDipyridamole may increase the anticoagulant activities of Dextran.
Dextran 40Dipyridamole may increase the anticoagulant activities of Dextran 40.
Dextran 70Dipyridamole may increase the anticoagulant activities of Dextran 70.
Dextran 75Dipyridamole may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Dipyridamole can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Dipyridamole.
DichlorvosThe therapeutic efficacy of Dichlorvos can be decreased when used in combination with Dipyridamole.
DiclofenacThe serum concentration of Dipyridamole can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Diclofenamide.
DicoumarolDipyridamole may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Dipyridamole.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dipyridamole.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Dipyridamole.
DigoxinThe serum concentration of Dipyridamole can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Dipyridamole.
DihydroergotamineThe serum concentration of Dipyridamole can be increased when it is combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Dipyridamole.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dipyridamole.
DinutuximabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dinutuximab.
DitazoleDipyridamole may increase the anticoagulant activities of Ditazole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Dipyridamole.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Dipyridamole.
DonepezilThe therapeutic efficacy of Donepezil can be decreased when used in combination with Dipyridamole.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dipyridamole.
DoxepinThe serum concentration of Dipyridamole can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Dipyridamole can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Dipyridamole.
DronabinolThe serum concentration of Dipyridamole can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Dipyridamole can be increased when it is combined with Dronedarone.
Drotrecogin alfaDipyridamole may increase the anticoagulant activities of Drotrecogin alfa.
DuloxetineDipyridamole may increase the orthostatic hypotensive activities of Duloxetine.
EchothiophateThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Dipyridamole.
Edetic AcidDipyridamole may increase the anticoagulant activities of Edetic Acid.
EdoxabanDipyridamole may increase the anticoagulant activities of Edoxaban.
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Dipyridamole.
ElbasvirThe serum concentration of Dipyridamole can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Dipyridamole.
EmpagliflozinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dipyridamole.
EnoxaparinDipyridamole may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Dipyridamole can be increased when it is combined with Enzalutamide.
EpinastineEpinastine may increase the anticoagulant activities of Dipyridamole.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Dipyridamole.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dipyridamole.
EpoprostenolDipyridamole may increase the anticoagulant activities of Epoprostenol.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dipyridamole.
EptifibatideEptifibatide may increase the anticoagulant activities of Dipyridamole.
ErgonovineThe serum concentration of Dipyridamole can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Dipyridamole can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Dipyridamole.
ErythromycinThe serum concentration of Dipyridamole can be decreased when it is combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Dipyridamole.
EsmololDipyridamole may increase the bradycardic activities of Esmolol.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Dipyridamole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Dipyridamole.
EstramustineThe serum concentration of Dipyridamole can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Dipyridamole can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Dipyridamole.
EstroneThe serum concentration of Dipyridamole can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Dipyridamole.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Dipyridamole.
Ethyl biscoumacetateDipyridamole may increase the anticoagulant activities of Ethyl biscoumacetate.
EtoposideThe serum concentration of Dipyridamole can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Dipyridamole can be increased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Dipyridamole.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Dipyridamole.
FelodipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Felodipine.
FentanylThe serum concentration of Dipyridamole can be increased when it is combined with Fentanyl.
FenthionThe therapeutic efficacy of Fenthion can be decreased when used in combination with Dipyridamole.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Dipyridamole.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Dipyridamole.
FibrinolysinDipyridamole may increase the anticoagulant activities of Fibrinolysin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Dipyridamole.
FluconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Dipyridamole can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Dipyridamole can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Dipyridamole can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Dipyridamole can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Dipyridamole.
FluvoxamineThe serum concentration of Dipyridamole can be increased when it is combined with Fluvoxamine.
Fondaparinux sodiumDipyridamole may increase the anticoagulant activities of Fondaparinux sodium.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dipyridamole.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Dipyridamole.
GalantamineThe therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Dipyridamole.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Dipyridamole.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Dipyridamole.
GenisteinThe serum concentration of Dipyridamole can be increased when it is combined with Genistein.
Ginkgo bilobaThe therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Dipyridamole.
GlucosamineGlucosamine may increase the antiplatelet activities of Dipyridamole.
GlyburideThe serum concentration of Dipyridamole can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Dipyridamole can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Dipyridamole can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Dipyridamole.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Dipyridamole.
GuanfacineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Dipyridamole.
HeparinDipyridamole may increase the anticoagulant activities of Heparin.
HexobarbitalHexobarbital may increase the hypotensive activities of Dipyridamole.
HirulogDipyridamole may increase the anticoagulant activities of Hirulog.
Huperzine AThe therapeutic efficacy of Huperzine A can be decreased when used in combination with Dipyridamole.
HydralazineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Dipyridamole.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dipyridamole.
IbudilastIbudilast may increase the anticoagulant activities of Dipyridamole.
IbudilastDipyridamole may increase the antiplatelet activities of Ibudilast.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Dipyridamole.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dipyridamole.
Icosapent ethylDipyridamole may increase the antiplatelet activities of Icosapent ethyl.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Dipyridamole.
IfenprodilIfenprodil may increase the anticoagulant activities of Dipyridamole.
IfenprodilDipyridamole may increase the antiplatelet activities of Ifenprodil.
IloprostDipyridamole may increase the anticoagulant activities of Iloprost.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Dipyridamole.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Dipyridamole.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Dipyridamole.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Dipyridamole.
IndenololDipyridamole may increase the bradycardic activities of Indenolol.
IndinavirThe serum concentration of Dipyridamole can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Dipyridamole.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Dipyridamole.
IrbesartanThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Dipyridamole.
IsavuconazoniumThe serum concentration of Dipyridamole can be increased when it is combined with Isavuconazonium.
IsoflurophateThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Dipyridamole.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dipyridamole.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dipyridamole.
ItraconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Dipyridamole can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Dipyridamole.
KetamineThe serum concentration of Dipyridamole can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Dipyridamole.
KetoconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Ketoconazole.
LabetalolDipyridamole may increase the bradycardic activities of Labetalol.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dipyridamole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Dipyridamole.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Dipyridamole.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Dipyridamole.
LapatinibThe serum concentration of Dipyridamole can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Dipyridamole.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Dipyridamole.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Dipyridamole.
LepirudinDipyridamole may increase the anticoagulant activities of Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Dipyridamole.
LevobunololDipyridamole may increase the bradycardic activities of Levobunolol.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dipyridamole.
LevodopaDipyridamole may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Dipyridamole.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Dipyridamole.
LevothyroxineThe serum concentration of Dipyridamole can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Dipyridamole can be increased when it is combined with Lidocaine.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dipyridamole.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Dipyridamole.
LiothyronineThe serum concentration of Dipyridamole can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Dipyridamole can be decreased when it is combined with Liotrix.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dipyridamole.
LomitapideThe serum concentration of Dipyridamole can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Dipyridamole.
LopinavirThe serum concentration of Dipyridamole can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Dipyridamole can be increased when it is combined with Loratadine.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Dipyridamole.
LovastatinThe serum concentration of Dipyridamole can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Dipyridamole can be decreased when it is combined with Lumacaftor.
MalathionThe therapeutic efficacy of Malathion can be decreased when used in combination with Dipyridamole.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Dipyridamole.
MaprotilineThe serum concentration of Dipyridamole can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Dipyridamole can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dipyridamole.
MefloquineThe therapeutic efficacy of Mefloquine can be decreased when used in combination with Dipyridamole.
MefloquineThe serum concentration of Dipyridamole can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Dipyridamole can be increased when it is combined with Megestrol acetate.
MemantineThe therapeutic efficacy of Memantine can be decreased when used in combination with Dipyridamole.
MeprobamateThe serum concentration of Dipyridamole can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dipyridamole.
MethadoneThe serum concentration of Dipyridamole can be increased when it is combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dipyridamole.
MethohexitalMethohexital may increase the hypotensive activities of Dipyridamole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Dipyridamole.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dipyridamole.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dipyridamole.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Dipyridamole.
MetipranololDipyridamole may increase the bradycardic activities of Metipranolol.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dipyridamole.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole.
MetoprololDipyridamole may increase the bradycardic activities of Metoprolol.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dipyridamole.
MibefradilThe serum concentration of Dipyridamole can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Dipyridamole can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Dipyridamole.
MifepristoneThe serum concentration of Dipyridamole can be decreased when it is combined with Mifepristone.
MilrinoneMilrinone may increase the anticoagulant activities of Dipyridamole.
MilrinoneDipyridamole may increase the antiplatelet activities of Milrinone.
MinaprineThe therapeutic efficacy of Minaprine can be decreased when used in combination with Dipyridamole.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dipyridamole.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Dipyridamole.
MitomycinThe serum concentration of Dipyridamole can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Dipyridamole can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Dipyridamole.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Dipyridamole.
MorphineThe serum concentration of Morphine can be increased when it is combined with Dipyridamole.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dipyridamole.
NadololDipyridamole may increase the bradycardic activities of Nadolol.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Dipyridamole.
NadroparinDipyridamole may increase the anticoagulant activities of Nadroparin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Dipyridamole.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Dipyridamole.
NaltrexoneThe serum concentration of Dipyridamole can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Dipyridamole can be increased when it is combined with Naringenin.
NCX 4016Dipyridamole may increase the anticoagulant activities of NCX 4016.
NebivololThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nebivolol.
NefazodoneThe serum concentration of Dipyridamole can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Dipyridamole can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Dipyridamole.
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Dipyridamole.
NeostigmineThe serum concentration of Dipyridamole can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nesiritide.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dipyridamole.
NicorandilNicorandil may increase the hypotensive activities of Dipyridamole.
NifedipineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nifedipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Dipyridamole.
NimesulideNimesulide may increase the anticoagulant activities of Dipyridamole.
NimesulideDipyridamole may increase the antiplatelet activities of Nimesulide.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dipyridamole.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Dipyridamole.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dipyridamole.
NitrazepamThe serum concentration of Dipyridamole can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Dipyridamole can be increased when it is combined with Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dipyridamole.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dipyridamole.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Dipyridamole.
NorethisteroneThe serum concentration of Dipyridamole can be decreased when it is combined with Norethisterone.
ObinutuzumabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Dipyridamole.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dipyridamole.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Dipyridamole.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Dipyridamole.
OmeprazoleThe serum concentration of Dipyridamole can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Dipyridamole.
OtamixabanDipyridamole may increase the anticoagulant activities of Otamixaban.
OxprenololDipyridamole may increase the bradycardic activities of Oxprenolol.
P-NitrophenolThe serum concentration of Dipyridamole can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Dipyridamole can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Dipyridamole can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Dipyridamole.
PantoprazoleThe serum concentration of Dipyridamole can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.
ParnaparinDipyridamole may increase the anticoagulant activities of Parnaparin.
ParoxetineThe serum concentration of Dipyridamole can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Dipyridamole.
PenbutololDipyridamole may increase the bradycardic activities of Penbutolol.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Dipyridamole.
PentobarbitalPentobarbital may increase the hypotensive activities of Dipyridamole.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Dipyridamole.
Pentosan PolysulfateDipyridamole may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Dipyridamole.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Dipyridamole.
PhenindioneDipyridamole may increase the anticoagulant activities of Phenindione.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Dipyridamole.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Dipyridamole.
PhenprocoumonDipyridamole may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Dipyridamole.
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Dipyridamole.
PimozideThe serum concentration of Dipyridamole can be increased when it is combined with Pimozide.
PindololDipyridamole may increase the bradycardic activities of Pindolol.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Dipyridamole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Dipyridamole.
PlasminDipyridamole may increase the anticoagulant activities of Plasmin.
Platelet Activating FactorThe serum concentration of Dipyridamole can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Dipyridamole.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Dipyridamole.
PosaconazoleThe serum concentration of Dipyridamole can be increased when it is combined with Posaconazole.
PractololDipyridamole may increase the bradycardic activities of Practolol.
PrasugrelDipyridamole may increase the anticoagulant activities of Prasugrel.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Dipyridamole.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dipyridamole.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Dipyridamole.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Dipyridamole.
PrimidonePrimidone may increase the hypotensive activities of Dipyridamole.
ProbenecidThe serum concentration of Dipyridamole can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Dipyridamole can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Dipyridamole.
PromethazineThe serum concentration of Dipyridamole can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Dipyridamole can be increased when it is combined with Propafenone.
PropranololDipyridamole may increase the bradycardic activities of Propranolol.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Dipyridamole.
Protein CDipyridamole may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeDipyridamole may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Dipyridamole can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Dipyridamole.
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dipyridamole.
QuercetinThe serum concentration of Dipyridamole can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Quetiapine.
QuinacrineThe serum concentration of Dipyridamole can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Dipyridamole.
QuinidineThe serum concentration of Dipyridamole can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Dipyridamole.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dipyridamole.
RanitidineThe serum concentration of Dipyridamole can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Dipyridamole.
ReboxetineThe serum concentration of Dipyridamole can be increased when it is combined with Reboxetine.
RegadenosonThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Regadenoson.
RegorafenibThe serum concentration of Dipyridamole can be increased when it is combined with Regorafenib.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dipyridamole.
ResveratrolResveratrol may increase the anticoagulant activities of Dipyridamole.
ResveratrolDipyridamole may increase the antiplatelet activities of Resveratrol.
ReteplaseDipyridamole may increase the anticoagulant activities of Reteplase.
ReviparinDipyridamole may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the anticoagulant activities of Dipyridamole.
RidogrelDipyridamole may increase the antiplatelet activities of Ridogrel.
RifampicinThe serum concentration of Dipyridamole can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Dipyridamole.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Dipyridamole.
RilpivirineThe serum concentration of Dipyridamole can be increased when it is combined with Rilpivirine.
RiociguatDipyridamole may increase the hypotensive activities of Riociguat.
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Dipyridamole.
RisperidoneDipyridamole may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Dipyridamole can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Dipyridamole.
RivaroxabanDipyridamole may increase the anticoagulant activities of Rivaroxaban.
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Dipyridamole.
RolapitantThe serum concentration of Dipyridamole can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Dipyridamole.
RosiglitazoneDipyridamole may increase the anticoagulant activities of Rosiglitazone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dipyridamole.
SaquinavirThe serum concentration of Dipyridamole can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Dipyridamole.
SCH-530348SCH-530348 may increase the anticoagulant activities of Dipyridamole.
SCH-530348Dipyridamole may increase the antiplatelet activities of SCH-530348.
ScopolamineThe serum concentration of Dipyridamole can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Dipyridamole.
SelegilineThe serum concentration of Dipyridamole can be increased when it is combined with Selegiline.
SelexipagDipyridamole may increase the anticoagulant activities of Selexipag.
SertralineThe serum concentration of Dipyridamole can be increased when it is combined with Sertraline.
SevofluraneSevoflurane may increase the anticoagulant activities of Dipyridamole.
SevofluraneDipyridamole may increase the antiplatelet activities of Sevoflurane.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Dipyridamole.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Dipyridamole.
SimvastatinThe serum concentration of Dipyridamole can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Dipyridamole can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Dipyridamole.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Dipyridamole.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Dipyridamole.
SotalolDipyridamole may increase the bradycardic activities of Sotalol.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Dipyridamole.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Dipyridamole.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Dipyridamole.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dipyridamole.
SRT501SRT501 may increase the anticoagulant activities of Dipyridamole.
SRT501Dipyridamole may increase the antiplatelet activities of SRT501.
St. John's WortThe serum concentration of Dipyridamole can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Dipyridamole can be increased when it is combined with Staurosporine.
StreptokinaseDipyridamole may increase the anticoagulant activities of Streptokinase.
StreptozocinThe serum concentration of Dipyridamole can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Dipyridamole can be increased when it is combined with Sulfinpyrazone.
SulodexideDipyridamole may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Dipyridamole can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Dipyridamole can be increased when it is combined with Sunitinib.
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole.
TacrineThe serum concentration of Dipyridamole can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Dipyridamole can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Dipyridamole.
TamoxifenThe serum concentration of Dipyridamole can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Dipyridamole.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Dipyridamole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dipyridamole.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Dipyridamole.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dipyridamole.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Dipyridamole.
TenecteplaseDipyridamole may increase the anticoagulant activities of Tenecteplase.
TerazosinThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Terazosin.
TerfenadineThe serum concentration of Dipyridamole can be increased when it is combined with Terfenadine.
TesmilifeneTesmilifene may increase the anticoagulant activities of Dipyridamole.
TesmilifeneDipyridamole may increase the antiplatelet activities of Tesmilifene.
TestosteroneThe serum concentration of Dipyridamole can be increased when it is combined with Testosterone.
ThiamylalThiamylal may increase the hypotensive activities of Dipyridamole.
ThiopentalThiopental may increase the hypotensive activities of Dipyridamole.
TicagrelorDipyridamole may increase the anticoagulant activities of Ticagrelor.
TicagrelorThe serum concentration of Dipyridamole can be increased when it is combined with Ticagrelor.
TiclopidineTiclopidine may increase the anticoagulant activities of Dipyridamole.
TimololDipyridamole may increase the bradycardic activities of Timolol.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Dipyridamole.
TinzaparinDipyridamole may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Dipyridamole.
TirofibanTirofiban may increase the anticoagulant activities of Dipyridamole.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dipyridamole.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Dipyridamole.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Dipyridamole.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dipyridamole.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Dipyridamole.
TositumomabThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dipyridamole.
TranilastTranilast may increase the anticoagulant activities of Dipyridamole.
TranilastDipyridamole may increase the antiplatelet activities of Tranilast.
TrapidilTrapidil may increase the anticoagulant activities of Dipyridamole.
TrapidilDipyridamole may increase the antiplatelet activities of Trapidil.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Dipyridamole.
TrazodoneThe serum concentration of Dipyridamole can be decreased when it is combined with Trazodone.
TreprostinilDipyridamole may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of Dipyridamole.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dipyridamole.
TrichlorfonThe therapeutic efficacy of Trichlorfon can be decreased when used in combination with Dipyridamole.
TrifluoperazineThe serum concentration of Dipyridamole can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Dipyridamole can be increased when it is combined with Triflupromazine.
TriflusalDipyridamole may increase the anticoagulant activities of Triflusal.
TrimethoprimThe serum concentration of Dipyridamole can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Dipyridamole can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Dipyridamole can be increased when it is combined with Troleandomycin.
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Dipyridamole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Dipyridamole.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Dipyridamole.
UrokinaseDipyridamole may increase the anticoagulant activities of Urokinase.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dipyridamole.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Dipyridamole.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Dipyridamole.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Dipyridamole.
VinblastineThe serum concentration of Dipyridamole can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Dipyridamole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Dipyridamole.
VincristineThe serum concentration of Dipyridamole can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Dipyridamole can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Dipyridamole.
Vitamin EVitamin E may increase the antiplatelet activities of Dipyridamole.
VorapaxarDipyridamole may increase the anticoagulant activities of Vorapaxar.
WarfarinDipyridamole may increase the anticoagulant activities of Warfarin.
XimelagatranDipyridamole may increase the anticoagulant activities of Ximelagatran.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Dipyridamole.
ZimelidineThe serum concentration of Dipyridamole can be increased when it is combined with Zimelidine.
Food Interactions
  • Coffee and tea can decrease the effect of dipyridamole.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:
PDE10A
Uniprot ID:
Q9Y233
Molecular Weight:
88411.71 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999 Jun 25;274(26):18438-45. [PubMed:10373451 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, PubMed:15489334). Specifically regulates nitric-oxide-generated cGMP (PubMed:15489334).
Gene Name:
PDE5A
Uniprot ID:
O76074
Molecular Weight:
99984.14 Da
References
  1. Kulkarni SK, Patil CS: Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):789-99. [PubMed:15672122 ]
  2. Santini F, Casali G, Franchi G, Auriemma S, Lusini M, Barozzi L, Favaro A, Messina A, Mazzucco A: Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults. Int J Cardiol. 2005 Aug 18;103(2):156-63. [PubMed:16080974 ]
  3. Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J: Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia. 2006 Aug;26(8):925-33. [PubMed:16886928 ]
  4. Jackson EK, Ren J, Zacharia LC, Mi Z: Characterization of renal ecto-phosphodiesterase. J Pharmacol Exp Ther. 2007 May;321(2):810-5. Epub 2007 Feb 16. [PubMed:17308037 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.
Gene Name:
ADA
Uniprot ID:
P00813
Molecular Weight:
40764.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. [PubMed:11856762 ]
  2. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
  3. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name:
ABCC5
Uniprot ID:
O15440
Molecular Weight:
160658.8 Da
References
  1. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003 May;63(5):1094-103. [PubMed:12695538 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 02:25